Authors

    Language

    English

    Publication Date

    6-25-2025

    Journal

    Journal of the American Chemical Society

    DOI

    10.1021/jacs.4c17876

    PMID

    40493376

    PMCID

    PMC12203648

    PubMedCentral® Posted Date

    6-27-2025

    PubMedCentral® Full Text Version

    Author MSS

    Abstract

    Antibiotics are essential for modern medicine, but their use drives the evolution of antimicrobial resistance (AMR) that limits the long-term efficacy of any one drug. To keep pace with AMR and preserve our ability to treat bacterial infections, it is essential that we identify antibiotics with new structures and targets that are not affected by clinical resistance. Historically, most developmental candidates for antibiotics have come from microbial natural products, as they feature chemical structures and biological activities that have been honed over millions of years of evolution. Unfortunately, as classical bioactivity screens for natural product discovery are blind to the pharmacological properties of their hits, they often identify molecules with functional groups that limit their utility as drugs. One prominent example is actinonin, an inhibitor of bacterial peptide deformylase (PDF) whose activity is dependent on a hydroxamate moiety associated with toxicity

    Keywords

    Amidohydrolases, Biological Products, Anti-Bacterial Agents, Enzyme Inhibitors, Genome, Bacterial, Hydroxamic Acids, Microbial natural products, genome-mining, biosynthesis

    Published Open-Access

    yes

    nihms-2091082-f0001.jpg (107 kB)
    Graphical Abstract

    Share

    COinS
     
     

    To view the content in your browser, please download Adobe Reader or, alternately,
    you may Download the file to your hard drive.

    NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.